Contineum Therapeutics, Inc.
CTNM
28 insider filings · Latest: Jul 8, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | Feb 26 9:40 PM | Carmine N. StengoneDirector, CEO and President | Sale | 2,700 | $16.02 | $43.2K | 14,954(D) | View → |
| Feb 24, 2026 | Feb 26 9:40 PM | Carmine N. StengoneDirector, CEO and President | Sale | 4,400 | $16.02 | $70.5K | 14,954(D) | View → |
| Feb 25, 2026 | Feb 26 9:39 PM | Daniel S. LorrainChief Scientific Officer | Sale | 3,824 | $16.01 | $61.2K | 156,052(D) | View → |
| Feb 24, 2026 | Feb 26 9:39 PM | Daniel S. LorrainChief Scientific Officer | Sale | 4,300 | $16.03 | $68.9K | 156,052(D) | View → |
| Feb 19, 2026 | Feb 20 9:05 PM | Daniel S. LorrainChief Scientific Officer | Sale | 100 | $16.00 | $1.6K | 156,052(D) | View → |
| Feb 11, 2026 | Feb 13 9:27 PM | Carmine N. StengoneDirector, CEO and President | Sale | 400 | $16.00 | $6.4K | 14,954(D) | View → |
| Feb 11, 2026 | Feb 13 9:26 PM | Daniel S. LorrainChief Scientific Officer | Sale | 400 | $16.00 | $6.4K | 156,052(D) | View → |
| Feb 11, 2026 | Feb 11 9:29 PM | DANIEL LORRAIN | Proposed Sale | 16,050 | $15.75 | $252.8K | — | View → |
| Feb 11, 2026 | Feb 11 9:29 PM | CARMINE STENGONE | Proposed Sale | 7,500 | $15.75 | $118.1K | — | View → |
| Feb 3, 2026 | Feb 5 9:24 PM | Daniel S. LorrainChief Scientific Officer | Sale | 4,170 | $14.94 | $62.3K | 156,052(D) | View → |
| Feb 3, 2026 | Feb 3 9:32 PM | DANIEL LORRAIN | Proposed Sale | 4,170 | $14.38 | $60.0K | — | View → |
| Jan 28, 2026 | Jan 30 9:52 PM | Tim WatkinsCMO & Head of Development | Sale | 3,611 | $14.18 | $51.2K | 0(D) | View → |
| Jan 5, 2026 | Jan 5 9:42 PM | DANIEL LORRAIN | Proposed Sale | 4,170 | $11.39 | $47.5K | — | View → |
| Dec 29, 2025 | Dec 29 9:25 PM | TIMOTHY WATKINS | Proposed Sale | 10,833 | $12.41 | $134.4K | — | View → |
| Dec 23, 2025 | Dec 23 9:20 PM | DANIEL LORRAIN | Proposed Sale | 4,170 | $12.26 | $51.1K | — | View → |
| Nov 18, 2024 | Nov 18 10:05 PM | DANIEL LORRAIN | Proposed Sale | 26,370 | $17.21 | $453.8K | — | View → |
← Previous
Page 2 of 2
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | Jul 10 9:20 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 25 | $1.01 | 33,257(D) | View → |
| Jul 8, 2026 | Jul 10 9:20 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 1,015 | $1.01 | 33,282(D) | View → |
| Jul 8, 2026 | Jul 8 10:49 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 2,500 | $1.01 | 279,430(D) | View → |
| Jul 1, 2026 | Jul 2 9:47 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 4,183 | $1.01 | 34,297(D) | View → |
| Jun 30, 2026 | Jul 2 9:47 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 28,826 | $1.01 | 38,480(D) | View → |
| Jun 30, 2026 | Jul 1 11:04 PM | Tim WatkinsCMO & Head of Development | Option Exercise | 10,833 | $4.50 | 238,334(D) | View → |
| Jun 30, 2026 | Jul 1 11:04 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 10,000 | $1.26 | 118,417(D) | View → |
| Jun 26, 2026 | Jun 26 9:46 PM | Gines Diego MirallesDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:45 PM | Lori Lyons-WilliamsDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:44 PM | Olivia C WareDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:44 PM | Evert B. SchimmelpenninkDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:43 PM | Troy A. IgnelziDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:43 PM | Todd R. BradyDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Jun 26, 2026 | Jun 26 9:42 PM | Sarah BoyceDirector | Grant/Award | 19,000 | $14.19 | 19,000(D) | View → |
| Mar 2, 2026 | Mar 2 11:28 PM | Tim WatkinsCMO & Head of Development | Option Exercise | 3,611 | $4.50 | 249,167(D) | View → |
| Feb 25, 2026 | Feb 26 9:40 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 2,700 | $1.26 | 120,917(D) | View → |
| Feb 24, 2026 | Feb 26 9:40 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 4,400 | $1.26 | 123,617(D) | View → |
| Feb 25, 2026 | Feb 26 9:39 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 3,824 | $1.01 | 67,306(D) | View → |
| Feb 24, 2026 | Feb 26 9:39 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 4,300 | $1.01 | 71,130(D) | View → |
| Feb 19, 2026 | Feb 20 9:05 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 100 | $1.01 | 75,430(D) | View → |
Page 1 of 2
Next →